Investigational Drug Information for Momelotinib
✉ Email this page to a colleague
What is the drug development status for Momelotinib?
Momelotinib is an investigational drug.
There have been 16 clinical trials for Momelotinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 19th 2014.
The most common disease conditions in clinical trials are Polycythemia Vera, Polycythemia, and Thrombocytosis. The leading clinical trial sponsors are Sierra Oncology, Inc., Gilead Sciences, and CTI BioPharma.
There are three hundred and thirty-two US patents protecting this investigational drug and two international patents.
Summary for Momelotinib
| US Patents | 332 |
| International Patents | 2,865 |
| US Patent Applications | 963 |
| WIPO Patent Applications | 778 |
| Japanese Patent Applications | 239 |
| Clinical Trial Progress | Phase 3 (2014-06-19) |
| Vendors | 92 |
Recent Clinical Trials for Momelotinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM) | Sierra Oncology, Inc. | Phase 3 |
| Extended Access of Momelotinib in Adults With Myelofibrosis | Gilead Sciences | Phase 2 |
| Extended Access of Momelotinib in Adults With Myelofibrosis | Sierra Oncology, Inc. | Phase 2 |
Clinical Trial Summary for Momelotinib
Top disease conditions for Momelotinib
Top clinical trial sponsors for Momelotinib
US Patents for Momelotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Momelotinib | See Plans and Pricing | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | See Plans and Pricing |
| Momelotinib | See Plans and Pricing | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | See Plans and Pricing |
| Momelotinib | See Plans and Pricing | Bicyclic bromodomain inhibitors | Zenith Epigenetics Ltd. (Calgary, AB, CA) | See Plans and Pricing |
| Momelotinib | See Plans and Pricing | Methods for the treatment of HER2 amplified cancer | Pharmacyclics LLC (Sunnyvale, CA) | See Plans and Pricing |
| Momelotinib | See Plans and Pricing | Benzimidazole derivatives as bromodomain inhibitors | Gilead Sciences, Inc. (Foster City, CA) | See Plans and Pricing |
| Momelotinib | See Plans and Pricing | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Momelotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Momelotinib | Australia | AU2015244171 | 2034-04-11 | See Plans and Pricing |
| Momelotinib | Australia | AU2015244179 | 2034-04-11 | See Plans and Pricing |
| Momelotinib | Canada | CA2945128 | 2034-04-11 | See Plans and Pricing |
| Momelotinib | Canada | CA2945129 | 2034-04-11 | See Plans and Pricing |
| Momelotinib | China | CN106414451 | 2034-04-11 | See Plans and Pricing |
| Momelotinib | China | CN106459063 | 2034-04-11 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
